Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and solid returns. The good news is that the company could still have plenty of room to grow, and that's why it deserves a closer look this year. Let's dig deeper into Exelixis. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join St ...